FAYE M JOHNSON to Lung Neoplasms
This is a "connection" page, showing publications FAYE M JOHNSON has written about Lung Neoplasms.
Connection Strength
1.685
-
A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia. 2018 10; 20(10):975-984.
Score: 0.128
-
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 2016 Jul 26; 7(30):47998-48010.
Score: 0.110
-
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686.
Score: 0.105
-
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1.
Score: 0.097
-
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012 Sep; 11(9):2021-32.
Score: 0.084
-
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012 May 30; 4(136):136ra70.
Score: 0.083
-
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
Score: 0.074
-
Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010 Jul 01; 11(4):238-42.
Score: 0.072
-
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat. 2010 Jun; 13(3):67-78.
Score: 0.072
-
EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009 Dec; 2(12):1039-49.
Score: 0.070
-
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009 Nov 15; 15(22):6852-61.
Score: 0.069
-
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol. 2009 Oct; 6(10):562-3.
Score: 0.069
-
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009 Jul 01; 15(13):4423-30.
Score: 0.067
-
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008 Jul 10; 26(20):3460-2.
Score: 0.063
-
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):366-74.
Score: 0.053
-
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6924-32.
Score: 0.052
-
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
Score: 0.045
-
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
Score: 0.045
-
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021 11; 16(11):1821-1839.
Score: 0.039
-
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med. 2019 05; 11(5).
Score: 0.033
-
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol. 2018 06; 31(6):947-955.
Score: 0.031
-
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst. 2017 06 01; 109(6).
Score: 0.029
-
Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. Clin Cancer Res. 2017 Mar 01; 23(5):1299-1311.
Score: 0.028
-
Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget. 2016 Jan 05; 7(1):565-79.
Score: 0.027
-
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
Score: 0.025
-
Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol. 2013 Mar; 8(3):301-8.
Score: 0.022
-
Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun; 5(6 Suppl 3):S207-13.
Score: 0.018
-
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.
Score: 0.018
-
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009 May 20; 27(15):2516-22.
Score: 0.017
-
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther. 2008 Apr; 7(4):952-60.
Score: 0.016
-
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007 Jan; 170(1):366-76.
Score: 0.014
-
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. Mol Cancer Ther. 2016 11; 15(11):2758-2766.
Score: 0.007
-
Combating resistance to anti-IGFR antibody by targeting the integrin ?3-Src pathway. J Natl Cancer Inst. 2013 Oct 16; 105(20):1558-70.
Score: 0.006